Two genetically modified broadly neutralizing antibodies (bNAbs) protected rhesus macaques from an HIV-like virus, report scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. After introducing genetic mutations into two potent HIV bNAbs, researchers prepared intravenous infusions of two bNAbs known as 3BNC117-LS and 10-1074-LS.
HIV/AIDS News Releases
Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to an interim analysis of study data. In addition, the rate of HIV infection among participants in the open-label study, which has no placebo arm for comparison, is half of what might be expected in the absence of the ring, according to mathematical modeling that has significant limitations.
A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. Adults and adolescents in the trial were more likely to complete the short-course regimen—consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks—than the standard nine-month regimen of daily isoniazid.
After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed the virus for six months without additional treatment, according to scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants. The study will evaluate the current preferred first-line regimen for pregnant women recommended by the World Health Organization (WHO) and two regimens containing newer antiretroviral drugs that are becoming more widely used.
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. Previous research illustrated this relationship in monkeys infected with a simian form of HIV.
Experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have penned a New England Journal of Medicine perspective recognizing the United States President’s Emergency Plan for AIDS Relief (PEPFAR) for 15 years of implementing an innovative program to prevent, treat, and care for persons living with HIV and AIDS. The authors stress that continued support for the U.S.
A short-term pause in HIV treatment during a carefully monitored clinical trial does not lead to lasting expansion of the HIV reservoir nor cause irreversible damage to the immune system, new findings suggest.
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesMaureen M. Goodenow, Ph.D., Director, Office of AIDS Research
The National Institutes of Health and partners have launched a large clinical trial to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection. The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa. Of 1.8 million new HIV infections worldwide in 2016, 43 percent occurred in eastern and southern Africa, with women and girls disproportionately affected.
The first large-scale clinical trial of a long-acting injectable medication for HIV prevention in sexually active women has begun. The study in southern and eastern Africa will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every eight weeks can safely protect women at risk for HIV infection. The only drug regimen currently licensed for HIV pre-exposure prophylaxis, or PrEP, is the anti-HIV medication Truvada taken daily as an oral tablet. The U.S.
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections in a population.
Investigators found that HIV incidence dropped by 42 percent among nearly 18,000 people in Rakai District, Uganda, during a seven-year period in which the rates of HIV treatment and voluntary medical male circumcision increased significantly.
Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers report in Science today.
Scientists at the National Institutes of Health have expanded the understanding of how chronic inflammation and persistent immune activation associated with HIV infection drive cardiovascular disease risk in people living with HIV. People living with HIV are up to twice as likely to experience heart attacks, strokes and other forms of cardiovascular disease as people who do not have the virus, even when HIV infection is well-controlled with the use of antiretroviral therapy.
A monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe and acceptable in studies of adolescents, two teams of investigators reported today at the 9th IAS Conference on HIV Science in Paris. The experimental ring is designed for HIV prevention and the oral tablet is already used for this purpose in adults. Adherence to the ring was high, while adherence to the tablet was moderate and diminished substantially when study visits became less frequent.
Transgender women—people whose birth certificates indicate or once indicated male sex but who identify as women—are at high risk of HIV acquisition, and thus are a key population for HIV prevention and treatment efforts.
A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during infancy has suppressed the virus without anti-HIV drugs for eight and a half years, scientists reported today at the 9th IAS Conference on HIV Science in Paris. This case appears to be the third reported instance of sustained HIV remission in a child after early, limited anti-HIV treatment.
Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate vaccine safety and efficacy among women at risk of acquiring HIV.
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine design, and support further study of modified bovine antibodies as HIV therapeutics or prevention tools in humans, scientists reported in a paper published online today in Nature.
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesCarl W. Dieffenbach, Ph.D., Director, Division of AIDS, NIAID
Statement of Christine F. Sizemore, PhD., Richard Hafner, M.D., and Anthony S. Fauci, M.D. National Institute of Allergy and Infectious DiseasesNational Institutes of Health
Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.
Scientists at the National Institutes of Health have found that the presence of the protein alpha-4 beta-7 integrin on the surface of HIV and its monkey equivalent—simian immunodeficiency virus, or SIV—may help explain why an antibody protected monkeys from SIV in previous experiments.
The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet.
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesCarl W. Dieffenbach, Ph.D., Director, Division of AIDS, NIAID
The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus. HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day.
Infusions of an anti-HIV antibody known as VRC01 were shown to be safe and maintained intended antibody concentrations in the blood of people living with HIV, according to two related studies by scientists at the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG). The antibody modestly suppressed blood levels of HIV in people who stopped taking antiretroviral therapy (ART), but the delay in the reappearance of virus was not clinically significant.
Achieving moderate reduction of new HIV infections among men who have sex with men (MSM) will depend on significantly increasing the percentage of HIV-infected MSM whose viral load is suppressed to undetectable levels, according to a new mathematical model based on data from Baltimore. Access and adherence to antiretroviral therapy are key to sustained HIV suppression, which dramatically reduces the risk of transmitting HIV to others.
Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear. This finding is among several insights gleaned about experiences of women who used the ring during the ASPIRE study, also known as MTN-020, announced today at the HIV Research for Prevention (HIVR4P) meeting in Chicago.
Scientists at the National Institutes of Health (NIH) and Emory University have experimentally induced sustained remission of SIV, the simian form of HIV, in infected monkeys. The animals’ immune systems have been suppressing the virus to undetectable levels for as long as 23 months since the monkeys completed an investigational treatment regimen. In addition, the regimen has led to the near-complete replenishment of key immune cells that SIV had destroyed, something unachievable with antiretroviral therapy (ART) alone. The findings will be published in the Oct.
People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report. While bNAbs cannot completely clear HIV infections in people who have already acquired the virus, many scientists believe a successful preventive HIV vaccine must induce bNAbs
Although antiretroviral therapy (ART) can reduce the amount of HIV in the blood to an undetectable level in most chronically infected people, it cannot eliminate reservoirs of HIV that persist in latently infected immune cells.
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.
For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India.
A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent. This finding is being reported today at a press briefing at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa, and will be presented in more detail tomorrow in a lecture at the conference.
The National Institutes of Health has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research.
The development of an effective vaccine to prevent HIV infections would represent a critical step toward ending the HIV/AIDS pandemic. Thus far, the only large clinical trial for an HIV vaccine to show promise was the RV144 study conducted in Thailand in 2009, which resulted in a modest 31 percent reduction in infection. Researchers are working to improve on the results of RV144 and also have launched efforts to create vaccines that induce broadly neutralizing antibodies that can block a wide range of HIV variants.
Advances in HIV/AIDS research have given us the opportunity to transform the lives of those living with HIV while providing highly effective methods of preventing the infection. This progress has strengthened optimism for achieving a durable end to the HIV/AIDS pandemic.
An early-stage HIV vaccine clinical trial in South Africa has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection.
A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell.
Enrollment into a clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) investigating two different strategies to treat limited-stage AIDS-related Kaposi’s sarcoma was stopped due to futility—if continued, the study would be unlikely to detect a difference between the two study arms.
A single antibody infusion can protect monkeys against infection with an HIV-like virus for up to 23 weeks, researchers have found. The study, published in Nature, was led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and The Rockefeller University.
New research in monkeys exposed to SIV, the monkey equivalent of HIV, suggests that the virus spreads rapidly in the body and triggers early host responses that suppress antiviral immunity, thus promoting viral replication. The study, published in Cell, provides a detailed view of the period between initial mucosal exposure to the virus and the point at which it becomes detectable in the blood.
Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the AMP Studies, for antibody-mediated prevention, the trials will test whether giving people an investigational anti-HIV antibody called VRC01 as an intravenous infusion every 8 weeks is safe, tolerable and effective at preventing HIV infection.
A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) comparing three advanced Kaposi’s sarcoma chemotherapy regimens in combination with antiretroviral treatment (ART) for patients with AIDS will no longer enroll participants in the study arm testing the oral chemotherapy drug etoposide.
Antibodies derived from a type of immune cell found in unusually high numbers in HIV-infected individuals with chronically uncontrolled virus levels are less effective at neutralizing HIV than antibodies derived from a different type of immune cell more common in people without HIV, scientists report.
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.
New findings suggest that black men who have sex with men (BMSM) with access to a novel coordinated care program can adhere to pre-exposure prophylaxis (PrEP), a medication regimen that helps prevent HIV infection in uninfected individuals.
Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.
The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found.
In HIV-infected patients undergoing antiretroviral therapy (ART), ongoing HIV replication in lymphoid tissues such as the lymph nodes helps maintain stores, or reservoirs, of the virus, a new study funded by the National Institutes of Health suggests.
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report.
Scientists from the National Institute of Allergy and Infectious Diseases argue that the results of three large clinical trials definitively prove that the benefits of starting antiretroviral therapy early in HIV infection outweigh any theoretical risk.
When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as both treatment and prevention.
The U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs)
Recent research has yielded new information about immune responses associated with—and potentially responsible for—protection from HIV infection, providing leads for new strategies to develop an HIV vaccine.
National Institute of Allergy and Infectious Diseases& scientists offer a historical perspective on the search for a safe, effective HIV vaccine and describe how they influence current promising approaches in HIV vaccinology.
Antiretroviral treatment that consistently suppresses HIV is highly effective at preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, investigators report.
Lower levels of cholesterol in certain immune cells-a result of enhanced cholesterol metabolism within those cells-may help explain why some HIV-infected people are able to naturally control disease progression..
A trio of studies describes advances toward the development of an HIV vaccine. The study teams demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.
A single infusion of an experimental anti-HIV antibody called 3BNC117 resulted in significantly decreased HIV levels that persisted for as long as 28 days in HIV-infected individuals, according to Phase 1 clinical trial findings published online in Nature.
A study by National Institutes of Health grantees suggests that the best time to start treatment for HIV infection also should be based on how much time has elapsed since becoming HIV-infected.
For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.
A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period.
A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.
The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa. The results from the trial, called HVTN 097, bode well for plans to test a similar experimental vaccine regimen in South Africa beginning in 2015 in an effort to build upon the results of the RV144 study.
The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy (ART) as well as "elite controllers" who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population. The study is funded by NIH's National Institute of Allergy and Infectious Diseases (NIAID).
New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects.
The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health, both part of the National Institutes of Health, recently expanded the scientific scope of an HIV-cure related funding announcement to allow for a broader range of studies and approaches.